^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AB-201

    i
    Other names: AB-201, GCC2003, HER2 CAR-NK, GCC-2003
    Company:
    Artiva Biotherapeutics, GC Biopharma
    Drug class:
    HER2 inhibitor
    Related drugs:
    8ms
    A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Artiva Biotherapeutics, Inc. | N=133 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 expression
    |
    cyclophosphamide • fludarabine IV • AB-201
    almost3years
    A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors (clinicaltrials.gov)
    P1/2, N=133, Not yet recruiting, Artiva Biotherapeutics, Inc. | Initiation date: Mar 2023 --> Aug 2023
    Trial initiation date
    |
    HER-2 expression
    |
    cyclophosphamide • fludarabine IV • AB-201